Journal article
Replication‐mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA‐dependent protein kinase and dissociates RPA:DNA‐PK complexes
The EMBO journal, Vol.18(5), pp.1397-1406
03/01/1999
DOI: 10.1093/emboj/18.5.1397
PMCID: PMC1171229
PMID: 10064605
Abstract
Replication protein A (RPA) is a DNA single‐strand binding protein essential for DNA replication, recombination and repair. In human cells treated with the topoisomerase inhibitors camptothecin or etoposide (VP‐16), we find that RPA2, the middle‐sized subunit of RPA, becomes rapidly phosphorylated. This response appears to be due to DNA‐dependent protein kinase (DNA‐PK) and to be independent of p53 or the ataxia telangiectasia mutated (ATM) protein. RPA2 phosphorylation in response to camptothecin required ongoing DNA replication. Camptothecin itself partially inhibited DNA synthesis, and this inhibition followed the same kinetics as DNA‐PK activation and RPA2 phosphorylation. DNA‐PK activation and RPA2 phosphorylation were prevented by the cell‐cycle checkpoint abrogator 7‐hydroxystaurosporine (UCN‐01), which markedly potentiates camptothecin cytotoxicity. The DNA‐PK catalytic subunit (DNA‐PKcs) was found to bind RPA which was replaced by the Ku autoantigen upon camptothecin treatment. DNA‐PKcs interacted directly with RPA1 in vitro. We propose that the encounter of a replication fork with a topoisomerase–DNA cleavage complex could lead to a juxtaposition of replication fork‐associated RPA and DNA double‐strand end‐associated DNA‐PK, leading to RPA2 phosphorylation which may signal the presence of DNA damage to an S‐phase checkpoint mechanism.
Keywords: camptothecin/DNA damage/DNA‐dependent protein kinase/RPA2 phosphorylation
Details
- Title: Subtitle
- Replication‐mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA‐dependent protein kinase and dissociates RPA:DNA‐PK complexes
- Creators
- Rong‐Guang Shao - Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of HealthChun‐Xia Cao - Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of HealthHongliang Zhang - Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of HealthKurt W Kohn - Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of HealthMarc S Wold - Department of Biochemistry, University of IowaYves Pommier - Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health
- Resource Type
- Journal article
- Publication Details
- The EMBO journal, Vol.18(5), pp.1397-1406
- Publisher
- John Wiley & Sons, Ltd; Chichester, UK
- DOI
- 10.1093/emboj/18.5.1397
- PMID
- 10064605
- PMCID
- PMC1171229
- ISSN
- 0261-4189
- eISSN
- 1460-2075
- Number of pages
- 10
- Language
- English
- Date published
- 03/01/1999
- Academic Unit
- Radiation Oncology; Biochemistry and Molecular Biology
- Record Identifier
- 9984025268202771
Metrics
14 Record Views